>>>
>>> IT'S
>>> IT'S A MAJOR HEALTH HEADLINE.
HEADLINE.
HEADLINE. THOUSANDS OF WOMEN COULD SKIP
CHEMOTHERAPY WHEN TREATING
BREAST CANCER.
BREAST CANCER. IT WAS FOUND THAT THERE IS NO
EVIDENCE THAT CHEMO WOULD HELP
TO BEAT BREAST CANC+@ER OR
PREVENT IT FROM COMING UP.
THE RESULTS ARE EXPECTED TO
SPARE 70,000 PATIENTS A YEAR IN
THE U.S. THE FINDINGS INDICATE
THAT YOU MAY BE BETTER OFF WITH
SURGERY AND HORMONE THERAPY AND
THIS DOES NOT INCLUDE ALL KINDS
OF BREAST CANCER OR LATER STAGE
CANCER.
CANCER.
CANCER. JOINING ME IS THE PROFESSOR
FROM UT SOUTHWESTERN MEDICAL
CENTER, THE CANCER CENTER.
YOU SAID THIS STUDY TOOK A LONG
TIME TO COME.
>> IT DID.
IT OPENED 12 YEARS AGO IN 2006.
IT ROLLED OVER 10,000 WOMEN
QLDING A FEW HUNDRED WHO WERE
INELIGIBLE, SO 9700 WOMEN WERE
INCLUDED IN THE FINAL RESULT.
WHAT WE LEARNED IS THAT IN
WOMEN WHOSE BREAST CANCER IS
POSITIVE FOR ESTROGEN OR
PROGESTERONE RECEPTORS,
PROGESTERONE RECEPTORS, NEGATIVE BRACA GENE NOW CAN BE
SPARED CHEMOTHERAPY.
SPARED CHEMOTHERAPY. >> WOW.
>> WOW.
>> WOW. BUT YOU SAID THIS TEST IS NOT
FOR EVERYBODY.
FOR EVERYBODY. >> THAT'S CORRECT.
+@ REALLY, THE TEST IS FOR TUMORS
THAT ARE ESTROGEN RECEPTOR
POSITIVE AND/OR PROGESTERONE
RECEPTOR POSITIVE, AND IT'S NOW
DONE IN WOMEN WITH 1 TO 3
POSITIVE LYMPH NODES AND WE USE
IT IN THAT SETTING AS WELL.
THE ER POSITIVE BREAST CANCER
REPRESENTS UPTO 70% OF BREAST
CANCER IN THE UNITED STATES,
PARTICULARLY I OE IN
MENOPAUSE.
MENOPAUSE. FOR YOEOE,IT'S A
LITTLE LOWER.
LITTLE LOWER. THE RESULTS ARE BASED ON THIS
TEST.
TEST.
TEST. AND
TEST. AND THE ETLOOKS AT THE
GENOMIC ACTIVATION OF 16 GENES
IN BREAST CANCR AND LOOKING
AT THE PATTERN OF ACTIVATION
AND DE-ACTIVATION, THEY WERE
ABLE TO COMPARE TO WOMEN WHO
HAD BEEN TREATED MANY YEARS
PREVIOUSLY DDWITH THESE
VARIOUS GENE PATTERNS.
THAT WAS HOW THEY VALIDATED IT.
WHAT THEY WERE ABLE TO DO IS
RECONSTRUCT WHAT THEY CALLED A
RECURRENT SCOR
RECURRENT SCOR THIS APS TO WOMEN WITH
RECURRENT SCORES BETWEN11 AND
25, AND THAT'S IN THE MIDDLE,
THE INTERMEDIATE RISK.
ONE CAVEAT, FOR WOMEN UNDER 50,
FOR SCORES BETWEEN 16 AND 25,
THEY STILL BENEFIT FOR
CHEMOTHERAPY.
CHEMOTHERAPY. BUT FOR OLDER WOMEN, OVER 50,
THEY GAIN NO BENEFIT IF THEIR
SCORE IS UP TO 25.
>> I HAVE DONE PLENTY OF
STORIES ABOUT BREAST CANCER.
AS YOU WERE SAYING THIS IS ONE
OF THE LARGEST S+@TUDIES THAT W
DONE.
DONE.
DONE. >>
DONE. >> IT'S THE SINGLE LARGEST
BREAST CANCER TREATMENT STUDY
EVER DON+@E IN THE UNITED STATE
>> HOW COULD THIS BE A GAME
CHANGER?
CHANGER?
CHANGER? >> WELL, I THINK IT'S GOING TO
+@PREVENT THOUSANDS OF WOMEN A
YEAR FROM HAVING TO GET
CHEMOTHERAPY.
CHEMOTHERAPY. IT'S ALREADY CHANGING THE
PRACTICE.
PRACTICE.
PRACTICE. WE HAVE SEEN THE INTERIM
RESULTS COME OUT.
>> LITTLE BY LITTLE.
>> LITTLE BY LITTLE, WE FELT
MORE COMFORTABLE NOT
RECOMMENDING OLDER WOMEN+@ WITH
SCORES OF 18, 20, 22, NOT
RECOMMENDING CHEMOTHERAPY TO
THEM.
THEM.
THEM. WE
THEM. WE HAVE ALREADY BEGUN TO CHANGE
HOW WE APPROACH BREAST CANCER.
THE RISK OF TOXICITY IS
SIGN+@IFICANT, AND NOW WE KNOW
+@
SIGN+@IFICANT, AND NOW WE KNOW THERE IS NO BENE+@FIT.
WE DON'T +@WANT TO GIVE THEM
+@
WE DON'T +@WANT TO GIVE THEM TOXIC TREATMENT THAT WON'T HELP
THEM.
THEM.
THEM. >>
THEM. >> NOT AT ALL.
DOCTOR, THANK YOU FOR JOINING
US.
US.
US. WE
US. WE WILL BE BACK WITH ANOTHER
CHECK ON THE WEATHER